Skip to main content

Coronavirus Disease 2019 (COVID-19)

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
NCT04409509 | PHASE 2 | INTERVENTIONAL

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

Trial Information
14 Sites
124 Participants
Recruiting
18 Years to 7 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Nova Clinical Research, LLC
Bradenton,Florida,United States,34209
Theia Clinical Research, LLC
Saint Petersburg,Florida,United States,33707
MercyOne North Iowa Medical Center
Mason City,Iowa,United States,50401
Northeast Iowa Medical Education Foundation
Waterloo,Iowa,United States,50702
Lahey Hospital and Medical Center
Burlington,Massachusetts,United States,01805
University of Mississippi Medical Center
Jackson,Mississippi,United States,39216
Holy Name Hospital
Teaneck,New Jersey,United States,07666
Inspira Health Center Vineland
Vineland,New Jersey,United States,08360
Sisters of Charity Hospital St. Joseph's Campus
Buffalo,New York,United States,14225
Carolina Institute for Clinical Research
Fayetteville,North Carolina,United States,28304
Monument Health Clinical Research
Rapid City,South Dakota,United States,57701
PharmaTex Research
Amarillo,Texas,United States,79109
UT Health Science Center, McGovern Medical School
Houston,Texas,United States,77030
Inova Alexandria Hospital
Alexandria,Virginia,United States,22304

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov